Inovio Pharmaceuticals (NASDAQ:INO) said its lead candidate INO-3107 remains the company’s central focus as the biotechnology firm works through the U.S. regulatory review process and prepares for a potential commercial launch in recurrent respiratory papillomatosis, or RRP.
During the company’s first-quarter 2026 earnings call, President and Chief Executive Officer Dr. Jacqueline Shea said Inovio is focused on advancing INO-3107 toward its Oct. 30, 2026, PDUFA target date. The therapy is being reviewed by the U.S. Food and Drug Administration under the Accelerated Approval Program.
FDA Review Continues With No New Significant Mid-Cycle Issues
Chief Medical Officer Dr. Michael Sumner said the FDA has been actively reviewing the biologics license application since accepting it in December 2025. The agency completed its standard mid-cycle review and raised no new significant issues, according to Inovio.
However, the company is still awaiting an informal meeting with the FDA to discuss INO-3107’s eligibility for accelerated approval. Sumner said the agency is continuing to review an assessment aid submitted by Inovio in February that outlines the company’s rationale for accelerated approval eligibility.
Sumner said Inovio believes INO-3107 meets the relevant criteria because it addresses an unmet need and could provide a meaningful therapeutic benefit over existing treatment options. He pointed to three factors: efficacy data from a Phase 1/2 trial, a safety profile that does not require surgery during the dosing window to maintain minimal residual disease, and a differentiated mechanism of action.
According to Sumner, most patients in the Phase 1/2 trial experienced a 50% to 100% reduction in surgeries in the first year, with continued clinical improvement in the second year. He also said the product’s mechanism may help treat patients who are not served by the currently approved gorilla adenovirus-based immunotherapy.
Inovio has also submitted an updated protocol for a required confirmatory trial and is awaiting FDA feedback. Shea said feedback on the confirmatory study design is expected to be tied to the informal meeting and the broader discussion of the review pathway.
Commercial Preparations Underway
Chief Commercial Officer Steve Egge said Inovio is preparing for a potential U.S. launch in 2026 and plans to manage commercialization itself with support from a contract sales organization.
Egge said the company has completed targeting, segmentation and product positioning work, and has engaged or identified several commercial partners, including a third-party logistics provider, specialty distributor, specialty pharmacy, patient hub and agency of record.
He said Inovio is also studying the launch of a competitor’s recently approved product to refine its own commercial plans. Egge said INO-3107 would not face some of the same launch challenges because it does not require an ultra-cold chain and does not require surgery during the dosing window to maintain minimal residual disease.
In response to an analyst question, Egge said published estimates often cite about 14,000 RRP patients, though he said Inovio’s claims-data work suggests that figure may be a significant underestimate. He also noted that Precigen has cited 27,000 RRP patients. Egge said Inovio expects the existing product to have single-digit penetration in its first year, leaving “the vast majority” of the opportunity available if INO-3107 reaches the market.
Pipeline Work Continues Through Partnerships
Shea said most company resources are directed toward INO-3107, but Inovio continues to use partnerships to advance other pipeline programs.
In March, Inovio announced a collaboration with Akeso to evaluate INO-5412 in combination with Akeso’s novel dual checkpoint inhibitor as a potential treatment for glioblastoma. The study will be part of a Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute.
The company also highlighted progress with its DNA-encoded protein, or dPROT, platform. Shea said Inovio presented preclinical data targeting factor VIII production in hemophilia A and is developing additional rare disease targets, including Fabry disease and hypophosphatasia. She said the company is in discussions with potential partners to accelerate development of the platform.
First-Quarter Financial Results
Chief Financial Officer Peter Kies said Inovio ended the first quarter with $37.7 million in cash equivalents and short-term investments, down from $58.5 million at the end of 2025.
The company completed an underwritten public equity offering in April 2026, generating net proceeds of approximately $16 million after expenses. Kies said the additional capital extends Inovio’s estimated cash runway into the first quarter of 2027, beyond the INO-3107 PDUFA date.
- First-quarter operating expenses were $21.9 million, down 13% from $25.1 million in the prior-year quarter.
- Net loss was $19.7 million, or $0.28 per share, compared with a net loss of $19.7 million, or $0.51 per share, in the first quarter of 2025.
- The company estimates operational net cash burn of approximately $18 million for the second quarter of 2026.
Shea closed the call by saying Inovio remains focused on meeting upcoming INO-3107 milestones and advancing other pipeline candidates while working with the RRP Foundation and broader patient community.
About Inovio Pharmaceuticals (NASDAQ:INO)
Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
